TRIANA Biomedicines to Present New Cancer Drug TRI-611 Data at American Association for Cancer Research Annual Meeting 2026

TRIANA Biomedicines, a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult-to-drug disease targets.  

It will present data highlighting the first-in-class clinical stage compound TRI-611 as a selective, brain-penetrant molecular glue degrader for the treatment of anaplastic lymphoma kinase–positive (ALK+) non-small cell lung cancer (NSCLC). 

According to Towards Healthcare, the Induced proximity molecules market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 4.99 billion in 2026 to approximately USD 23.32 billion by 2035, representing a compound annual growth rate (CAGR) of 18.7% from 2026 to 2035. Growth is driven by the increasing pharmaceutical investments, driven by the need to address previously undruggable targets, and the adoption of these approaches necessitates highly specific and adaptable drug modalities, with projections indicating a substantial increase in market value in the coming years. 

About TRI-611 

TRI-611 is an investigational oral small molecule therapy designed as a potent, brain-penetrant molecular glue degrader targeting ALK fusion proteins in patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC). It works by engaging the body's innate protein-degradation machinery, promoting the degradation of ALK fusion proteins, which are crucial for the growth and survival of ALK+ NSCLC.  

It has been granted Fast Track designation by the FDA, indicating its potential to address unmet medical needs in the treatment of ALK+ NSCLC.  

About CCNE1  

CCNE1, or Cyclin E1, is a protein-coding gene located on chromosome 19. It plays a crucial role in the cell cycle by forming a complex with CDK2, which is essential for the transition from the G1 phase to the S phase (DNA replication). It has been linked to tumorigenesis, particularly in various cancers, leading to chromosome instability and contributing to aggressive disease progression. 

It offers a unique approach to targeting this key cancer driver by harnessing the cell’s protein degradation machinery to substantially decrease excess CCNE1 and halt the growth of CCNE1-dependent tumor cells. ​ 

A recent report by Towards Healthcare highlights that the Induced proximity molecules market is witnessing growth driven by the paradigm shift in drug discovery, the emergence of proximity-based approaches like PROTACs and molecular glues, and the increasing prevalence of chronic and complex diseases. The market is also being accelerated by the integration of advanced technologies such as artificial intelligence, high-throughput screening, and structural biology. 

North America leads the market due to its strong biotechnology infrastructure, high R&D expenditure, and a favorable regulatory environment. The Asia Pacific region is emerging as a significant growth engine, driven by increasing investments in biomedical research, expanding pharmaceutical manufacturing capabilities, and rising healthcare expenditure.